Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine plus gefitinib for first-line EGFR-mutant lung adenocarcinoma
ChiCTR1800016339Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of berberine and gefitinib in Non-small cell lung cancer adenocarcinoma (NSCLC) and non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: CT imaging and Blood examination. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
berberinegefitinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800016339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016339.